• Spyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE trial of SPY003 in ulcerative colitis.
• Findings showed meaningful improvement in disease activity, supporting SPY003’s potential as a competitive anti-IL-23 option.
• The safety profile was consistent with the IL-23 drug class, supporting continued development in combination regimens.
• Enrollment continues in SKYLINE Part B, which tests monotherapies and pairwise combinations; topline induction results are expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080800PRIMZONEFULLFEED9822405) on September 08, 2026, and is solely responsible for the information contained therein.